Acute kidney injury is a common complication of decompensated cirrhosis, frequently requires hospitalization, and carries a high short-term mortality. This population experiences several characteristic types of acute kidney injury: hypovolemic-mediated (prerenal), ischemic/nephrotoxic-mediated (acute-tubular necrosis), and hepatorenal syndrome. Prerenal acute kidney injury is treated with volume resuscitation. Acute-tubular necrosis is treated by optimizing perfusion pressure and discontinuing the offending agent. Hepatorenal syndrome, a unique physiology of decreased effective arterial circulation leading to renal vasoconstriction and ultimately acute kidney injury, is treated with plasma expansion with albumin and splanchnic vasoconstrictors such as terlipressin or norepinephrine. Common acute stressors such as bleeding, infection, and volume depletion often contribute to multifactorial acute kidney injury. Even with optimal medical management, many clinicians are faced with the challenge of initiating renal replacement therapy in these patients. This article reviews the epidemiology, indications, and complex considerations of renal replacement therapy for acute kidney injury in decompensated cirrhosis.
Keyphrases
- acute kidney injury
- liver failure
- cardiac surgery
- newly diagnosed
- ejection fraction
- respiratory failure
- heart failure
- end stage renal disease
- hepatitis b virus
- healthcare
- aortic dissection
- cardiac arrest
- chronic kidney disease
- risk factors
- case report
- atrial fibrillation
- mental health
- palliative care
- prognostic factors
- randomized controlled trial
- brain injury
- cardiovascular events
- computed tomography
- peritoneal dialysis
- extracorporeal membrane oxygenation
- oxidative stress
- acute respiratory distress syndrome
- cardiopulmonary resuscitation